Reference number : GC-2017-Q1-00574, amendment number : , agreement type : G, recipient legal name : Sinton, David (University of Toronto), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Idea to Innovation, program name french : De l'idée à l'innovation, program purpose english : DigiSperm is a rapid, point-of-care, low-cost device that uses paper-based microfluidic technology to quantify male fertility potential.  The device simultaneously measures three critical semen parameters for male fertility diagnosis in 10 min: live sperm concentration, motile sperm concentration, and motility. In preliminary side-by-side clinical testing, DigiSperm provided identical outcomes to the current clinical gold-standard, computer-assisted semen analysis (CASA) - an expensive lab technique to which few have access. In contrast, DigiSperm provides direct visual readout with straightforward and quantitative analysis of semen parameters, allowing direct imaging with a smartphone app for instantaneous analysis, readout, tracking and communication of the health result. Our medical collaborators refer to this technology as a 'fitbit for sperm', referring to the popular mobile health monitoring app. Technical improvements and proof-of-concept validation testing are required, however, to adapt this device for widespread commercial mobile health diagnosis. The targeted research and proof-of-concept testing proposed here are essential to engaging investors, in keeping with the I2I Phase I program._x000D_
_x000D_
The proposed project has three specific objectives: i) develop a robust user-friendly fluid delivery interface; ii) optimize the device for smartphone/mobile health diagnosis; iii) perform necessary clinical validation and testing essential to engage early-stage investment._x000D_
_x000D_
The project benefits from a strong network of support and collaborations including Dr. Keith Jarvi (Head of Urology at Mount Sinai Hospital), the Hannam Fertility Centre, MaRS Innovation, the Kangaroo Group (Productization consultants), and the makers of ClearBlue (the worldwide standard in female fertility tests), in addition to cash support for addition patenting costs from the U of T._x000D_
_x000D_
_x000D_
_x000D_
_x000D_, program purpose french : DigiSperm is a rapid, point-of-care, low-cost device that uses paper-based microfluidic technology to quantify male fertility potential.  The device simultaneously measures three critical semen parameters for male fertility diagnosis in 10 min: live sperm concentration, motile sperm concentration, and motility. In preliminary side-by-side clinical testing, DigiSperm provided identical outcomes to the current clinical gold-standard, computer-assisted semen analysis (CASA) - an expensive lab technique to which few have access. In contrast, DigiSperm provides direct visual readout with straightforward and quantitative analysis of semen parameters, allowing direct imaging with a smartphone app for instantaneous analysis, readout, tracking and communication of the health result. Our medical collaborators refer to this technology as a 'fitbit for sperm', referring to the popular mobile health monitoring app. Technical improvements and proof-of-concept validation testing are required, however, to adapt this device for widespread commercial mobile health diagnosis. The targeted research and proof-of-concept testing proposed here are essential to engaging investors, in keeping with the I2I Phase I program._x000D_
_x000D_
The proposed project has three specific objectives: i) develop a robust user-friendly fluid delivery interface; ii) optimize the device for smartphone/mobile health diagnosis; iii) perform necessary clinical validation and testing essential to engage early-stage investment._x000D_
_x000D_
The project benefits from a strong network of support and collaborations including Dr. Keith Jarvi (Head of Urology at Mount Sinai Hospital), the Hannam Fertility Centre, MaRS Innovation, the Kangaroo Group (Productization consultants), and the makers of ClearBlue (the worldwide standard in female fertility tests), in addition to cash support for addition patenting costs from the U of T._x000D_
_x000D_
_x000D_
_x000D_
_x000D_, agreement title english : Mobile heath app screening for male fertility, agreement title french : Mobile heath app screening for male fertility, agreement number : I2IPJ, agreement value : 122372.0, agreement start date : 2017-06-14, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2018-2019), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada